TegoScience Inc.

KOSDAQ:A191420 Stock Report

Market Cap: ₩130.6b

TegoScience Past Earnings Performance

Past criteria checks 2/6

TegoScience's earnings have been declining at an average annual rate of -3.7%, while the Biotechs industry saw earnings growing at 3.8% annually. Revenues have been growing at an average rate of 0.3% per year. TegoScience's return on equity is 7.1%, and it has net margins of 52.7%.

Key information

-3.7%

Earnings growth rate

-3.6%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate0.3%
Return on equity7.1%
Net Margin52.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Are TegoScience Inc.'s (KOSDAQ:191420) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

Feb 16
Are TegoScience Inc.'s (KOSDAQ:191420) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

How Much Of TegoScience Inc. (KOSDAQ:191420) Do Insiders Own?

Jan 12
How Much Of TegoScience Inc. (KOSDAQ:191420) Do Insiders Own?

Did You Miss TegoScience's (KOSDAQ:191420) Impressive 137% Share Price Gain?

Dec 08
Did You Miss TegoScience's (KOSDAQ:191420) Impressive 137% Share Price Gain?

Revenue & Expenses Breakdown

How TegoScience makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A191420 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 246,9273,6523,7322,410
30 Jun 246,9743,3523,6132,474
31 Mar 247,194-2,6593,4752,593
31 Dec 237,772-2,3233,6562,576
30 Sep 238,016-1,4042,1133,475
30 Jun 238,134-1,3012,8702,971
31 Mar 238,2022353,7292,027
31 Dec 227,6782653,5341,608
30 Sep 228,4261,3494,854412
30 Jun 228,3411,2544,0141,044
31 Mar 228,1624323,5622,062
31 Dec 218,3001393,9062,328
30 Sep 217,573-4794,1422,421
30 Jun 218,235714,0892,284
31 Mar 218,4559933,5881,992
31 Dec 208,7891,8313,0021,852
30 Sep 208,3231,7612,6711,759
30 Jun 207,5801,3382,5431,803
31 Mar 206,9831,2732,4371,732
31 Dec 196,3468562,4091,700
30 Sep 196,723-2,0582,6121,720
30 Jun 196,849-2,1422,7631,659
31 Mar 197,366-7762,9391,762
31 Dec 187,850-1,8263,1641,743
30 Sep 188,042-3,0713,2261,762
30 Jun 188,245-2,8883,3501,545
31 Mar 188,331-7,5153,4131,583
31 Dec 178,642-6,0213,3481,568
30 Sep 178,568-2,9853,1821,376
30 Jun 178,568-2,6103,0001,433
31 Mar 178,5497762,8791,415
31 Dec 168,3437722,8571,433
30 Sep 168,0491,8422,9071,583
30 Jun 167,9811,8412,8451,678
31 Dec 157,4921,4732,9251,605

Quality Earnings: A191420 has a large one-off gain of ₩3.6B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: A191420 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A191420 has become profitable over the past 5 years, growing earnings by -3.7% per year.

Accelerating Growth: A191420 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: A191420 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).

Return on Equity

High ROE: A191420's Return on Equity (7.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/22 22:07
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TegoScience Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Changhee WooIBK Securities Co. Ltd.
Seung-Ho LeeNH Investment & Securities Co., Ltd.